Immunovant faces high R&D costs, limited cash runway, and unproven clinical edge despite pipeline progress and deeper IgG ...

Recently, its 'batoclimab,' being developed as a treatment for autoimmune diseases, was designated as an orphan drug for thyroid eye disease in Japan, and it has achieved positive results in phase 3 ...

"Graves Disease Drugs Market"Graves' Disease Companies are Immunovant Sciences GmbH, Novartis Pharmaceuticals, Apitope International NV, AV7 Limited, Medtronic, Pfizer, Sanguine Biosciences ...

On Friday, H.C. Wainwright adjusted its price target on shares of Immunovant (NASDAQ: IMVT), reducing it to $35.00 from the previous target of $54.00, while maintaining a Buy rating on the company’s ...

We have consistently seen deeper and better responses that includes in our Graves' Phase IIa data for Batoclimab, where we had 60% of patients effectively off ATDs in the over 70% cohort compared ...

The company expects to achieve financial efficiencies in its IMVT-1402 development program by leveraging the data already available from batoclimab studies. Currently, Immunovant is developing ...